These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12446994)

  • 1. Long-term suppression of pituitary-gonadal function with three-month depot of leuprorelin acetate in a girl with central precocious puberty.
    Schroeter M; Baus I; Sippell WG; Partsch CJ
    Horm Res; 2002; 58(6):292-6. PubMed ID: 12446994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg).
    Carel JC; Lahlou N; Jaramillo O; Montauban V; Teinturier C; Colle M; Lucas C; Chaussain JL
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4111-6. PubMed ID: 12213857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial.
    Li WJ; Gong CX; Guo MJ; Xing J; Li T; Song WH; Luo XP; Wu D; Liang JP; Cao BY; Gu Y; Su C; Liang XJ; Liu M; Wang R; Li FT
    Chin Med J (Engl); 2015 May; 128(10):1314-20. PubMed ID: 25963350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
    Klein KO; Dragnic S; Soliman AM; Bacher P
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
    Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
    Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group.
    Carel JC; Lahlou N; Guazzarotti L; Joubert-Collin M; Roger M; Colle M; Chaussain JL
    Eur J Endocrinol; 1995 Jun; 132(6):699-704. PubMed ID: 7788009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty.
    Johnson SR; Nolan RC; Grant MT; Price GJ; Siafarikas A; Bint L; Choong CS
    J Paediatr Child Health; 2012 Mar; 48(3):E136-9. PubMed ID: 21564386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.
    Plosker GL; Brogden RN
    Drugs; 1994 Dec; 48(6):930-67. PubMed ID: 7533699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of central precocious puberty--can final height be improved? German/Dutch Central Precocious Puberty Study Group.
    Sippell WG
    Horm Res; 1994; 41 Suppl 2():14-5. PubMed ID: 8088698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leptin changes in Taiwanese girls with central precocious puberty before and during the GnRH agonist treatment.
    Su PH; Wang SL; Lin CY; Chen JY; Changlai CP; Jian SH; Chen SJ
    Acta Paediatr Taiwan; 2005; 46(5):278-83. PubMed ID: 16640001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.